Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.
Toshikazu MoriwakiShota FukuokaToshiki MasuishiAtsuo TakashimaYosuke KumekawaTakeshi KajiwaraKentaro YamazakiTaito EsakiAkitaka MakiyamaTadamichi DendaYukimasa HatachiTakeshi SutoNaotoshi SugimotoMasanobu EnomotoToshiaki IshikawaTomomi KashiwadaEiji OkiYoshito KomatsuAkihito TsujiKenji TsuchihashiDaisuke SakaiHideki UenoTakao TamuraKimihiro YamashitaYasuhiro ShimadaPublished in: International journal of clinical oncology (2019)
These prognostic scores are useful for identifying patients with mCRC who will obtain survival benefits from these drugs.